Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 6,435 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin to Skin Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Not applicable Interventional Results available

Women Empowered to Live With Lupus Study

NCT02988661
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Chronic Disease Self-management Program (CDSMP)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 1:41 PM EDT
Completed No phase listed Observational

Implementation of a Web-based Decision Aid for Breast Cancer Surgery

NCT03304002
View directory record Official record
Conditions
Breast Cancer, Surgery
Interventions
Breast Cancer Surgery Decision Aid
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03895203
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

NCT00368654
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Raptiva
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

NCT00109005
View directory record Official record
Conditions
Melanoma
Interventions
Revlimid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

NCT00722761
View directory record Official record
Conditions
Acne Vulgaris
Interventions
drospirenone and ethinyl estradiol, Placebo tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 23, 2026, 1:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate Safety, of NextraTM in Surgery to Fuse the Proximal-interphalangeal- Joints

NCT01604070
View directory record Official record
Conditions
Foot Diseases
Interventions
Not listed
Lead sponsor
eMedtrain Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Cambridge, Massachusetts • Vineland, New Jersey • Alexandria, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 23, 2026, 1:41 PM EDT
Terminated Phase 1 Interventional

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

NCT04948554
View directory record Official record
Conditions
Systemic Sclerosis With and Without Interstitial Lung Disease
Interventions
MK-2225, Placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 23, 2026, 1:41 PM EDT
Terminated Early Phase 1 Interventional

Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.

NCT03106766
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acne cream 2X, Acne cream 1X
Drug
Lead sponsor
Next Science TM
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

NCT03134222
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Lanraplenib, Filgotinib, Lanraplenib placebo, Filgotinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Beverly Hills, California • Fullerton, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Durapore vs. Hy-Tape to Secure The Endotracheal Tube

NCT03633877
View directory record Official record
Conditions
Erythema
Interventions
DuraporeTM and Hy-Tape®
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitization Study of ATx201 in Healthy Volunteers

NCT03375957
View directory record Official record
Conditions
Sensitivity, Contact
Interventions
ATx201, ATx201 Placebo Gel
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

NCT00071812
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
63
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 23, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional

Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer

NCT02008994
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Genomic and Proteomic Profiling
Other
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 23, 2026, 1:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

NCT02947022
View directory record Official record
Conditions
Headache, Cognitive Disturbance, Skin Hyperpigmentation, Arthralgia
Interventions
Calcium DTPA, Zinc DTPA
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

NCT05456529
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
North Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 23, 2026, 1:41 PM EDT
Terminated Phase 1 Interventional

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

NCT02012231
View directory record Official record
Conditions
Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
Interventions
PLX8394
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 23, 2026, 1:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

NCT02506153
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
552
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

NCT04048031
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement Capsules, Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

NCT05206331
View directory record Official record
Conditions
Breast Cancer
Interventions
contrast enhanced mammography, Iodinated Contrast Media (ICM)
Device · Drug
Lead sponsor
Margarita Louise Zuley
Other
Eligibility
30 Years and older · Female only
Enrollment
2,089 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

NCT07222995
View directory record Official record
Conditions
Skin Cancer
Interventions
Precision Prevention Booklet, Standard Prevention Booklet
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

NCT06023277
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ConvitVax
Biological
Lead sponsor
Jacinto Convit World Organization Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 2 Interventional

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

NCT00480753
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 23, 2026, 1:41 PM EDT